MaxCyte Inc [MXCT] stock is trading at $1.66, down -2.92%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MXCT shares have gain 10.67% over the last week, with a monthly amount glided 19.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MaxCyte Inc [NASDAQ: MXCT] stock has seen the most recent analyst activity on August 11, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, William Blair downgraded its rating to Mkt Perform on August 07, 2025. On July 22, 2025, Stephens initiated with a Overweight rating and assigned a price target of $6 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $7 on November 29, 2023. In a note dated August 24, 2021, Wedbush initiated an Outperform rating and provided a target price of $36 on this stock.
MaxCyte Inc [MXCT] stock has fluctuated between $1.26 and $5.20 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. MaxCyte Inc [NASDAQ: MXCT] shares were valued at $1.66 at the most recent close of the market. An investor can expect a potential return of 261.45% based on the average MXCT price forecast.
Analyzing the MXCT fundamentals
MaxCyte Inc [NASDAQ:MXCT] reported sales of 35.75M for the trailing twelve months, which represents a drop of -18.43%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -1.47%, Pretax Profit Margin comes in at -1.25%, and Net Profit Margin reading is -1.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.22 and Total Capital is -0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.6183 points at the first support level, and at 1.5767 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7333, and for the 2nd resistance point, it is at 1.8067.
Ratios To Look Out For
For context, MaxCyte Inc’s Current Ratio is 12.39. As well, the Quick Ratio is 11.71, while the Cash Ratio is 1.32. Considering the valuation of this stock, the price to sales ratio is 4.95, the price to book ratio is 0.93.
Transactions by insiders
Recent insider trading involved Hemrajani Rekha, Director, that happened on Jun 25 ’25 when 10684.0 shares were sold. CHIEF FINANCIAL OFFICER, Swirsky Douglas J completed a deal on Aug 13 ’25 to buy 50000.0 shares. Meanwhile, President and CEO Masoud Maher bought 75000.0 shares on Aug 13 ’25.
